Levels of Soluble Receptor for Advanced Glycation End Products in Acute Ischemic Stroke without a Source of Cardioembolism
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Low levels of soluble receptor for advanced glycation end products (sRAGE) are associated with three conventional vascular risk factors (3Fs: diabetes, hypertension, and hypercholesterolemia), nondiabetic coronary artery disease, and Alzheimer’s disease. However, the association between sRAGE and acute ischemic stroke (AS), especially AS without a source of cardioembolism, has not yet been established. Methods Patients with AS without a source of cardioembolism (n=259) and age-matched controls (n=300) were grouped according to the presence of 3Fs: AS patients with and without 3Fs (3Fs+ AS and 3Fs- AS, respectively) and controls with and without 3Fs (3Fs+ control and 3Fs- control, respectively). Levels of sRAGE were analyzed among the four groups. Results sRAGE was significantly higher in the controls than in the AS patients (855 pg/mL vs. 690 pg/mL, p<0.01). sRAGE was significantly higher in 3Fs- controls (996 pg/mL, p<0.05) than in 3Fs+ controls (721 pg/mL), and in AS group regardless of the 3Fs (629 pg/mL in 3Fsand 705 pg/mL in 3Fs+). The lowest tertile of sRAGE was associated with an increased risk of AS in the 3Fs- group [adjusted odds ratio (OR) 4.0, 95% confidence interval (CI) 1.6-10.3, p< 0.01] but not in the 3Fs+ group. The level of sRAGE was also correlated with neurological severity in the 3Fs- AS group (r=-0.32, p<0.05) but not in the 3Fs+ AS group. Conclusions Low plasma levels of sRAGE is a potential biomarker for the risk of AS and may reflect the neurological severity of the condition, especially in subjects without identifiable conventional risk factors.
Abstract
Background and Purpose Low levels of soluble receptor for advanced glycation end products (sRAGE) are associated with three conventional vascular risk factors (3Fs: diabetes, hypertension, and hypercholesterolemia), nondiabetic coronary artery disease, and Alzheimer’s disease. However, the association between sRAGE and acute ischemic stroke (AS), especially AS without a source of cardioembolism, has not yet been established. Methods Patients with AS without a source of cardioembolism (n=259) and age-matched controls (n=300) were grouped according to the presence of 3Fs: AS patients with and without 3Fs (3Fs+ AS and 3Fs- AS, respectively) and controls with and without 3Fs (3Fs+ control and 3Fs- control, respectively). Levels of sRAGE were analyzed among the four groups. Results sRAGE was significantly higher in the controls than in the AS patients (855 pg/mL vs. 690 pg/mL, p<0.01). sRAGE was significantly higher in 3Fs- controls (996 pg/mL, p<0.05) than in 3Fs+ controls (721 pg/mL), and in AS group regardless of the 3Fs (629 pg/mL in 3Fsand 705 pg/mL in 3Fs+). The lowest tertile of sRAGE was associated with an increased risk of AS in the 3Fs- group [adjusted odds ratio (OR) 4.0, 95% confidence interval (CI) 1.6-10.3, p< 0.01] but not in the 3Fs+ group. The level of sRAGE was also correlated with neurological severity in the 3Fs- AS group (r=-0.32, p<0.05) but not in the 3Fs+ AS group. Conclusions Low plasma levels of sRAGE is a potential biomarker for the risk of AS and may reflect the neurological severity of the condition, especially in subjects without identifiable conventional risk factors.
참고문헌 (23)
- Brett J, "Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues", Am J Pathol, 143, pp.1699~1712 (1993)
- Hori O, "The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and coexpression of rage and amphoterin in the developing nervous system", J Biol Chem, 270, pp.25752~25761 (1995)
- Stern D, "Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings", Adv Drug Deliv Rev, 54, pp.1615~1625 (2002)
- Basta G., "Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications", Atherosclerosis, 196, pp.9~21 (2008)
- Koyama H, "RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases", Mol Med, 13, pp.625~635 (2007)
- Ma L, "RAGE is expressed in pyramidal cells of the hippocampus following moderate hypoxic-ischemic brain injury in rats", Brain Res, 966, pp.167~174 (2003)
- Zhai DX, "RAGE expression is up-regulated in human cerebral ischemia and pMCAO rats", Neurosci Lett, 445, pp.117~121 (2008)
- Bucciarelli LG, "RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice", Circulation, 106, pp.2827~ (2002), 2835
- Basta G, "Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein", J Clin Endocrinol Metab, 91, pp.4628~4634 (2006)
- Geroldi D, "Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension", J Hypertens, 23, pp.1725~1729 (2005)
- Santilli F, "Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins", Free Radic Biol Med, 43, pp.1255~1262 (2007)
- Falcone C, "Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men", Arterioscler Thromb Vasc Biol, 25, pp.1032~1037 (2005)
- Emanuele E, "Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia", Arch Neurol, 62, pp.1734~1736 (2005)
- Adams HP Jr, "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment", Stroke, 24, pp.35~41 (1993)
- Nakamura K, "Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease", Diabetes Metab Res Rev, 23, pp.368~371 (2007)
- Nakamura K, "Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension", Microvasc Res, 70, pp.137~141 (2005)
- Yamagishi S, "Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes", Arterioscler Thromb Vasc Biol, 27, pp.e32~ (2007)
- Koyama H, "Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis", Arterioscler Thromb Vasc Biol, 25, pp.2587~2593 (2005)
- Katakami N, "Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications", Diabetes Care, 28, pp.2716~2721 (2005)
- Katakami N, "Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients", Atherosclerosis, 190, pp.22~23 (2007)
- Katakami N, "Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients", Diab Vasc Dis Res, 5, pp.190~197 (2008)
- Humpert PM, "Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes", Cardiovasc Diabetol, 6, pp.9~ (2007)
- 정근화, "Circulating Endothelial Progenitor Cells in Cerebrovascular Disease", Journal of Clinical Neurology, 4(4), pp.139~147 (2008), 대한신경과학회